{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:13:23Z","timestamp":1786979603638,"version":"build-2736575974"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T00:00:00Z","timestamp":1699920000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T00:00:00Z","timestamp":1699920000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Herz"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1007\/s00059-023-05221-2","type":"journal-article","created":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T10:02:29Z","timestamp":1699956149000},"page":"19-21","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Herzinsuffizienz: Leitlinien-Update der ESC 2023","Heart failure: update of the ESC 2023 guidelines"],"prefix":"10.1007","volume":"49","author":[{"given":"Johann","family":"Bauersachs","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samira","family":"Soltani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,14]]},"reference":[{"key":"5221_CR1","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/nejmoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray\u00a0JJV, Solomon\u00a0SD, Inzucchi\u00a0SE et\u00a0al (2019) Dapagliflozin in patients with heart failure and reduced ejection fraction. New Engl J Med 381:1995\u20132008. https:\/\/doi.org\/10.1056\/nejmoa1911303","journal-title":"New Engl J Med"},{"key":"5221_CR2","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/nejmoa2022190","volume":"383","author":"M Packer","year":"2020","unstructured":"Packer\u00a0M, Anker\u00a0SD, Butler\u00a0J et\u00a0al (2020) Cardiovascular and renal outcomes with Empagliflozin in heart failure. New Engl J Med 383:1413\u20131424. https:\/\/doi.org\/10.1056\/nejmoa2022190","journal-title":"New Engl J Med"},{"key":"5221_CR3","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/nejmoa2107038","volume":"385","author":"SD Anker","year":"2021","unstructured":"Anker\u00a0SD, Butler\u00a0J, Filippatos\u00a0G et\u00a0al (2021) Empagliflozin in heart failure with a\u00a0preserved ejection fraction. N\u00a0Engl J Med 385:1451\u20131461. https:\/\/doi.org\/10.1056\/nejmoa2107038","journal-title":"N Engl J Med"},{"key":"5221_CR4","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1056\/nejmoa2206286","volume":"387","author":"SD Solomon","year":"2022","unstructured":"Solomon\u00a0SD, McMurray\u00a0JJV, Claggett\u00a0B et\u00a0al (2022) Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N\u00a0Engl J Med 387:1089\u20131098. https:\/\/doi.org\/10.1056\/nejmoa2206286","journal-title":"N Engl J Med"},{"key":"5221_CR5","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehad195","author":"TA McDonagh","year":"2023","unstructured":"McDonagh\u00a0TA, Metra\u00a0M, Adamo\u00a0M et\u00a0al (2023) 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart\u00a0J. https:\/\/doi.org\/10.1093\/eurheartj\/ehad195","journal-title":"Eur Heart J"},{"key":"5221_CR6","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1016\/s0140-6736(22)02076-1","volume":"400","author":"A Mebazaa","year":"2022","unstructured":"Mebazaa\u00a0A, Davison\u00a0B, Chioncel\u00a0O et al (2022) Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a\u00a0multinational, open-label, randomised, trial. Lancet 400:1938\u20131952. https:\/\/doi.org\/10.1016\/s0140-6736(22)02076-1","journal-title":"Lancet"},{"key":"5221_CR7","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1016\/j.jacc.2023.03.426","volume":"81","author":"M Pagnesi","year":"2023","unstructured":"Pagnesi\u00a0M, Metra\u00a0M, Cohen-Solal\u00a0A et al (2023) Uptitrating treatment after heart failure hospitalization across the spectrum of left ventricular ejection fraction. J\u00a0Am Coll Cardiol 81:2131\u20132144. https:\/\/doi.org\/10.1016\/j.jacc.2023.03.426","journal-title":"J Am Coll Cardiol"},{"key":"5221_CR8","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1093\/eurheartj\/ehad266","volume":"44","author":"W Mullens","year":"2023","unstructured":"Mullens\u00a0W, Schulze\u00a0PC, Westphal\u00a0J et\u00a0al (2023) Great debate: in patients with decompensated heart failure, acetazolamide in addition to loop diuretics is the first choice. Eur Heart\u00a0J 44:2159\u20132169. https:\/\/doi.org\/10.1093\/eurheartj\/ehad266","journal-title":"Eur Heart J"},{"key":"5221_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01659-1","author":"AA Voors","year":"2022","unstructured":"Voors\u00a0AA, Angermann\u00a0CE, Teerlink\u00a0JR et\u00a0al (2022) The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a\u00a0multinational randomized trial. Nat Med. https:\/\/doi.org\/10.1038\/s41591-021-01659-1","journal-title":"Nat Med"},{"key":"5221_CR10","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1016\/s0140-6736(22)02083-9","volume":"400","author":"PR Kalra","year":"2023","unstructured":"Kalra\u00a0PR, Cleland\u00a0JGF, Petrie\u00a0MC et al (2023) Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial. Lancet 400:2199\u20132209. https:\/\/doi.org\/10.1016\/s0140-6736(22)02083-9","journal-title":"Lancet"},{"key":"5221_CR11","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1016\/s0140-6736(20)32339-4","volume":"396","author":"P Ponikowski","year":"2020","unstructured":"Ponikowski\u00a0P, Kirwan\u00a0B\u2011A, Anker\u00a0SD et al (2020) Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a\u00a0multicentre, double-blind, randomised, controlled trial. Lancet 396:1895\u20131904. https:\/\/doi.org\/10.1016\/s0140-6736(20)32339-4","journal-title":"Lancet"},{"key":"5221_CR12","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1056\/nejmoa2304968","volume":"389","author":"RJ Mentz","year":"2023","unstructured":"Mentz\u00a0RJ, Garg\u00a0J, Rockhold\u00a0FW et\u00a0al (2023) Ferric carboxymaltose in heart failure with iron deficiency. N\u00a0Engl J Med 389:975\u2013986. https:\/\/doi.org\/10.1056\/nejmoa2304968","journal-title":"N Engl J Med"},{"key":"5221_CR13","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/nejmoa2025845","volume":"383","author":"GL Bakris","year":"2020","unstructured":"Bakris\u00a0GL, Agarwal\u00a0R, Anker\u00a0SD et\u00a0al (2020) Effect of finerenone on chronic kidney disease outcomes in type\u00a02 diabetes. N\u00a0Engl J Med 383:2219\u20132229. https:\/\/doi.org\/10.1056\/nejmoa2025845","journal-title":"N Engl J Med"},{"key":"5221_CR14","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1056\/nejmoa2110956","volume":"385","author":"B Pitt","year":"2021","unstructured":"Pitt\u00a0B, Filippatos\u00a0G, Agarwal\u00a0R et\u00a0al (2021) Cardiovascular events with finerenone in kidney disease and type\u00a02 diabetes. N\u00a0Engl J Med 385:2252\u20132263. https:\/\/doi.org\/10.1056\/nejmoa2110956","journal-title":"N Engl J Med"},{"key":"5221_CR15","doi-asserted-by":"publisher","first-page":"ehab777","DOI":"10.1093\/eurheartj\/ehab777","volume":"43","author":"R Agarwal","year":"2021","unstructured":"Agarwal\u00a0R, Filippatos\u00a0G, Pitt\u00a0B et\u00a0al (2021) Cardiovascular and kidney outcomes with finerenone in patients with type\u00a02 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart\u00a0J 43:ehab777. https:\/\/doi.org\/10.1093\/eurheartj\/ehab777","journal-title":"Eur Heart J"}],"container-title":["Herz"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00059-023-05221-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00059-023-05221-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00059-023-05221-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,31]],"date-time":"2024-01-31T12:02:45Z","timestamp":1706702565000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00059-023-05221-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,14]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["5221"],"URL":"https:\/\/doi.org\/10.1007\/s00059-023-05221-2","relation":{"is-referenced-by":[{"id-type":"doi","id":"10.1007\/s40199-026-00637-7","asserted-by":"object"}]},"ISSN":["0340-9937","1615-6692"],"issn-type":[{"value":"0340-9937","type":"print"},{"value":"1615-6692","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,14]]},"assertion":[{"value":"15 October 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"J.\u00a0Bauersachs erhielt Honorare f\u00fcr Vortr\u00e4ge\/Beratung von Novartis, Vifor, Bayer, Pfizer, Boehringer Ingelheim, AstraZeneca, Cardior, CVRx, BMS, Norgine, Amgen, Corvia, Edwards, Roche, die nicht im Zusammenhang mit diesem Artikel stehen, und Forschungsunterst\u00fctzung f\u00fcr die Abteilung von Zoll, CVRx, Abiomed, Norgine, Roche, die nicht im Zusammenhang mit diesem Artikel steht. S.\u00a0Soltani erhielt Honorare f\u00fcr Vortr\u00e4ge\/Beratung von AstraZeneca, die nicht im Zusammenhang mit diesem Artikel stehen.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}